{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:17:10Z","timestamp":1768706230087,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical Co, Ltd, Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"Public Health Service Grant","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5U24-CA076518"],"award-info":[{"award-number":["5U24-CA076518"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["5U10HL069294"],"award-info":[{"award-number":["5U10HL069294"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["HHSH250201200016C"],"award-info":[{"award-number":["HHSH250201200016C"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"Office of Naval Research","doi-asserted-by":"publisher","award":["N00014-13-1-0039"],"award-info":[{"award-number":["N00014-13-1-0039"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"Office of Naval Research","doi-asserted-by":"publisher","award":["N00014-14-1-0028"],"award-info":[{"award-number":["N00014-14-1-0028"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"*Amgen, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008980","name":"Anonymous donation to the Medical College of Wisconsin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001738","name":"Be the Match Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001738","id-type":"DOI","asserted-by":"publisher"}]},{"name":"*Bristol Myers Squibb Oncology"},{"DOI":"10.13039\/100006436","name":"*Celgene Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"*Chimerix, Inc"},{"DOI":"10.13039\/100005895","name":"Fred Hutchinson Cancer Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005895","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gamida Cell Ltd"},{"DOI":"10.13039\/100004328","name":"Genentech, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"*Gilead Sciences, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005622","name":"Health Research, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001320","name":"Roswell Park Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006797","name":"HistoGenetics, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006797","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Incyte Corp"},{"DOI":"10.13039\/100011096","name":"*Jazz Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jeff Gordon Children's Foundation"},{"DOI":"10.13039\/100005189","name":"Leukemia & Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008980","name":"Medical College of Wisconsin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mesoblast"},{"name":"*Millennium: The Takeda Oncology Co"},{"DOI":"10.13039\/501100004176","name":"*Miltenyi Biotec, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004176","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Marrow Donor Program"},{"name":"Neovii Biotech NA, Inc"},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007072","name":"Onyx Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007072","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Optum Healthcare Solutions, Inc"},{"DOI":"10.13039\/100009155","name":"Otsuka America Pharmaceutical, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical Co, Ltd\u2013Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Oxford Immunotec"},{"name":"PerkinElmer, Inc"},{"DOI":"10.13039\/100014491","name":"Pharmacyclics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014491","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"*Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009996","name":"Sigma-Tau Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006399","name":"*Spectrum Pharmaceuticals, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015234","name":"*Sunesis Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015234","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Swedish Orphan Biovitrum, Inc"},{"DOI":"10.13039\/100017070","name":"Telomere Diagnostics, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017070","id-type":"DOI","asserted-by":"crossref"}]},{"name":"TerumoBCT"},{"DOI":"10.13039\/100007163","name":"Therakos, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007163","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004382","name":"*Wellpoint, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bbmt.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.bbmt.2016.04.013","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T02:06:33Z","timestamp":1462327593000},"page":"1424-1430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies"],"prefix":"10.1016","volume":"22","author":[{"given":"Marcelo C.","family":"Pasquini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Le-Rademacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Artz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo F.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Mineishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Kamishohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayesh","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Voravit","family":"Ratanatharathorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Sobecks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Burkart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Bredeson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.04.013_bib1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s002800050404","article-title":"Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy","volume":"37","author":"Bhagwatwar","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2016.04.013_bib2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","article-title":"Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide","volume":"309","author":"Santos","year":"1983","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.04.013_bib3","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","article-title":"Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen","volume":"70","author":"Tutschka","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.013_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","article-title":"Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.013_bib5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S1083-8791(00)70064-4","article-title":"Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study","volume":"6","author":"Andersson","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.013_bib6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.013_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbmt.2006.08.037","article-title":"Pharmacokinetics of once-daily intravenous busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule","volume":"13","author":"Madden","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.013_bib8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.013_bib9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","article-title":"Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS","volume":"14","author":"Andersson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.013_bib10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbmt.2013.11.027","article-title":"Fludarabine and exposure-targeted busulfan compares favorably with busulfan\/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity","volume":"20","author":"Bartelink","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.013_bib11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.bmt.1705770","article-title":"New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2","volume":"40","author":"Chae","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.013_bib12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.bbmt.2008.06.009","article-title":"Outcomes following HSCT using fludarabine, busulfan and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide","volume":"14","author":"Bredeson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.013_bib13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1200\/JCO.2011.40.2362","article-title":"Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine","volume":"31","author":"Lee","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.04.013_bib14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s12185-013-1460-3","article-title":"Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study","volume":"98","author":"Liu","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2016.04.013_bib15","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cycophosphamide versus bulsulfan plus fludarabine as a perparative regimen for allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia: an open-label, multicentre, ransomised, phase 3 trial","volume":"15","author":"Rambaldi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2016.04.013_bib16","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","article-title":"Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation","volume":"122","author":"Bredeson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.013_bib17","first-page":"187","article-title":"2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders","author":"Pasquini","year":"2013","journal-title":"Clin Transpl"},{"key":"10.1016\/j.bbmt.2016.04.013_bib18","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.013_bib19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.013_bib20","series-title":"Survival analysis: techniques for censored and truncated data","author":"Klein","year":"2003"},{"key":"10.1016\/j.bbmt.2016.04.013_bib21","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V80.7.1648.1648","article-title":"Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation","volume":"80","author":"Copelan","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.013_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00694339","article-title":"Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation","volume":"25","author":"Grochow","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2016.04.013_bib23","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood.V84.7.2144.2144","article-title":"Busulfan bioavailability","volume":"84","author":"Hassan","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.013_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2016.04.013_bib25","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.013_bib26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s12185-015-1756-6","article-title":"Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation","volume":"101","author":"Sato","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2016.04.013_bib27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/1078155214541571","article-title":"Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?","volume":"21","author":"Clemmons","year":"2015","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.bbmt.2016.04.013_bib28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-200241020-00002","article-title":"Cellular and clinical pharmacology of fludarabine","volume":"41","author":"Gandhi","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bbmt.2016.04.013_bib29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.013_bib30","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2002-11-3567","article-title":"Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells","volume":"102","author":"Bornhauser","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.04.013_bib31","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.bbmt.2011.12.584","article-title":"Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation","volume":"18","author":"Perkins","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.013_bib32","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/cncr.29087","article-title":"Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial","volume":"121","author":"Mohty","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2016.04.013_bib33","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.bbmt.2013.07.002","article-title":"Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation","volume":"19","author":"Russell","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.04.013_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2217\/pgs.12.185","article-title":"Role of pharmacogenetics in busulfan\/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation","volume":"14","author":"Hassan","year":"2013","journal-title":"Pharmacogenomics"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116300325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116300325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T06:49:25Z","timestamp":1690008565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116300325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1083879116300325"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.04.013","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}